Academic Research Consortium High Bleeding Risk Criteria associated with 2-year bleeding events and mortality after transcatheter aortic valve replacement discharge: a Japanese Multicentre Prospective OCEAN-TAVI Registry Study
暂无分享,去创建一个
G. Nakazawa | K. Takagi | M. Tabata | K. Hayashida | Fumiaki Yashima | Yusuke Watanabe | H. Ueno | S. Shirai | T. Naganuma | F. Yamanaka | Norio Tada | Masanori Yamamoto | K. Mizutani | M. Yamawaki | T. Okai | Tomohiro Yamaguchi | M. Ogawa | M. Yamamoto | Y. Watanabe | N. Tada | Mana Ogawa | F. Yashima | Tsukasa Okai
[1] J. Peper,et al. Assessment of the Academic Research Consortium for High Bleeding Risk Criteria in Patients Undergoing TAVR. , 2021, JACC. Cardiovascular interventions.
[2] Masato Nakamura,et al. Implications and characteristics of high bleeding risk in East Asian patients undergoing percutaneous coronary intervention: Start with what is right rather than what is acceptable. , 2020, Journal of cardiology.
[3] P. Stella,et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. , 2020, The New England journal of medicine.
[4] K. Tanabe,et al. High Bleeding Risk and Clinical Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention: the PENDULUM Registry. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[5] Samin K. Sharma,et al. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. , 2020, Journal of the American College of Cardiology.
[6] P. Stella,et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. , 2020, The New England journal of medicine.
[7] A. Ramzy,et al. Transcatheter aortic valve replacement in patients with severe aortic stenosis and active cancer: a systematic review and meta-analysis , 2020, Open Heart.
[8] W. Harmsen,et al. Long‐Term Outcomes After Transcatheter and Surgical Aortic Valve Replacement in Patients With Cirrhosis: A Guide for the Hepatologist , 2020, Hepatology.
[9] J. Tijssen,et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. , 2019, The New England journal of medicine.
[10] M. Toyofuku,et al. Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention. , 2019, Circulation. Cardiovascular interventions.
[11] A. Colombo,et al. Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.
[12] Angelo B. Biviano,et al. Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation. , 2019, JACC. Cardiovascular interventions.
[13] H. Okayama,et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.
[14] M. Price,et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention , 2019, Circulation.
[15] J. Leipsic,et al. Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients , 2019, The New England journal of medicine.
[16] Andrew S. Mugglin,et al. Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients , 2019, The New England journal of medicine.
[17] Deepak L. Bhatt,et al. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. , 2019, Journal of the American College of Cardiology.
[18] J. Eikelboom,et al. Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review. , 2019, JACC. Cardiovascular interventions.
[19] Deepak L. Bhatt,et al. Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs , 2018, Thrombosis and Haemostasis.
[20] K. Takagi,et al. Transcatheter aortic valve replacement outcomes in Japan: Optimized CathEter vAlvular iNtervention (OCEAN) Japanese multicenter registry. , 2019, Cardiovascular revascularization medicine : including molecular interventions.
[21] K. Takagi,et al. Elevation of B‐Type Natriuretic Peptide at Discharge is Associated With 2‐Year Mortality After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Insights From a Multicenter Prospective OCEAN‐TAVI (Optimized Transcatheter Valvular Intervention–Transcatheter Aortic Valve , 2017, Journal of the American Heart Association.
[22] S. Kohsaka,et al. Impact of the Clinical Frailty Scale on Outcomes After Transcatheter Aortic Valve Replacement , 2017, Circulation.
[23] Deepak L. Bhatt,et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials , 2017, The Lancet.
[24] R. Smalling,et al. The Society of Thoracic Surgery Risk Score as a Predictor of 30-Day Mortality in Transcatheter vs Surgical Aortic Valve Replacement: A Single-Center Experience and its Implications for the Development of a TAVR Risk-Prediction Model. , 2017, The Journal of invasive cardiology.
[25] John D Carroll,et al. 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. , 2017, The Annals of thoracic surgery.
[26] C. Held,et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial , 2016, European heart journal.
[27] M. Mack,et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.
[28] Sean M. O'Brien,et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality After Transcatheter Aortic Valve Replacement. , 2016, JAMA cardiology.
[29] Peter L Duffy,et al. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. , 2015, Journal of the American College of Cardiology.
[30] S. Windecker,et al. Stable coronary artery disease: revascularisation and invasive strategies , 2015, The Lancet.
[31] A. Go,et al. Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. , 2015, Journal of the American College of Cardiology.
[32] M. Mack,et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. , 2014, Journal of the American College of Cardiology.
[33] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[34] Pascal Leprince,et al. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score , 2014, Heart.
[35] A. Kirtane,et al. Incidence and effect of acute kidney injury after transcatheter aortic valve replacement using the new valve academic research consortium criteria. , 2013, The American journal of cardiology.
[36] Stuart J Pocock,et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.
[37] S. Pocock,et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.
[38] Wansu Chen,et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. , 2007, Journal of the American College of Cardiology.
[39] T. Yamaguchi. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. , 2000, Stroke.
[40] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.